What you need to know
John Theurer Cancer Center is now recruiting a Phase II clinical trial for pancreatic cancer called PROTACT (Precise RNAi for Obtaining Targeted Cancer Therapy).
During PROTACT treatment, a miniature biodegradable polymeric matrix called “LODER” that encompasses an anti KRAS(G12D) drug is inserted directly into the core of the solid tumor, using a standard Endoscope Ultrasound (EUS) procedure. Insertion usually does not require full anesthesia, and normally takes about 15 minutes.
Immediately after insertion the LODER releases the siG12D drug slowly in a controlled manner over 12-16 weeks.
Details
Recent studies have shown that in addition to extending overall progression-free survival, the LODER treatment may halt perineural invasion (PNI) and by that may reduce the development of pain (usually in the abdomen or back) in patients with pancreatic cancer.
For more information about the clinical trial visit, pancan-protact.com or call 201-488-3003.